Decompensated stage of cirrhosis
Conditions
Interventions
MNCs treatment group:Human cord blood mononuclear cells were intravenously transfused according to body weight, once a week, 4 times in total, 2×106/kg/ time
control group:conventional therapy
Sponsors
The Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Definite diagnostic basis of decompensated stage of cirrhosis. The diagnosis of cirrhosis can be based on the following criteria :(1) definite histological, endoscopic or imaging evidence of cirrhosis; (2) Patients without histological, endoscopic or imaging examination should meet 2 of the following 4 criteria: (1)Platelet count & LT; 100×10^9/L, no other reasons can be explained; (2)albumin = 7 and MELD score 30%, platelet > 50×10^9/L(if there is no obvious bleeding tendency, PLT can be included in 30-50×10^9/L patients), hemoglobin > 70g/L; 9.Female subjects of childbearing age agreed to use contraception throughout the study period.
Exclusion criteria
Exclusion criteria: 1.complicated with liver or any other type of malignant tumor; 2.patients with severe complications within 1 month (digestive tract hemorrhage/acute hemorrhage, hepatic encephalopathy (stage III-IV), severe/acute infection); 3.those who have received immunosuppressant or immunobooster treatment within 3 months; 4.those who have received blood transfusion or other blood products within 1 month; 5.Major organ transplant history or serious diseases of heart, lung, kidney, blood, endocrine and other systems; 6.a history of severe mental illness, especially depression; 7.Patients with unstable vital signs; 8.Patients with poor physical condition who cannot tolerate cell transplantation; 9.highly allergic or have a history of severe allergies; 10.HIV-positive persons; 11.those who used drugs or received methadone treatment within 1 year prior to the start of the study; 12.those who have a history of alcohol and drug abuse and failed to effectively quit; 13.Participated in other clinical trials within 3 months prior to enrollment; 14.pregnant women, breast-feeding women or those with recent birth plans; 15.those who are unable or unwilling to sign the informed consent or fail to comply with the test requirements; 16.a few excessively high expectations or unrealistic demands; 17.Other conditions that the investigator considers inappropriate for patients to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Child - Pugh score;MELD score;Laboratory indicators, clinical symptoms and signs;Sf-36 scale score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Imaging examination and endoscopic evaluation;Body composition related indicators; | — |
Countries
China
Contacts
Public ContactXue Jing
Outcome results
None listed